XPhyto Therapeutics Corp provided a product development report on its sublingual oral dissolvable film (ODF) biosensor development pipeline, noting that the “integration” of its wholly-owned German subsidiary, Vektor Pharma TF GmbH, and recently acquired 3a technologies, has created a “pipeline of rapid screening test products” with “near-term commercialization potential.”
The company's oral dissolvable products are based on the ODF platform technology developed by Baden-Württemberg-based Vektor, which incorporates proprietary biosensor molecules developed by XPhyto's recently acquired and wholly-owned Germany subsidiary, 3a-diagnostics GmbH, which is located southeast of Stuttgart, Germany.
XPhyto said 3a specializes in the development of rapid point-of-care pathogen screening tests with a pipeline of biosensor screening products for bacterial and viral infectious diseases, which include stomatitis, periimplantitis, periodontitis, group A strep, and influenza A.
Positive detection of the causative pathogen results in enzymatic release of an extreme (but safe) bitter compound, said the company. Moreover, no medical training, analytical equipment or power supply is required. Meanwhile, the biosensors function as “a quick test” for heightened levels of certain targeted diseases, bacteria, and viruses to indicate whether further medical attention is advisable.
Significantly, the global biosensor market is expected to reach US$42 billion by 2027, according to Global Market Insights.
In the third quarter of 2021, the company received an EU commercial registration number to sell its first biosensor for oral inflammation and is currently building a sales and marketing strategy focused on the oral health cosmetic dentistry market.
The company said it is reviewing its biosensor development pipeline to identify the priority commercialization programs, which will likely “include at least one oral health application,” said XPhyto. The Global Dental Services Market was approximately US$435 billion in 2021, according to MedicalExpo e-magazine and is expected to touch US$698.8 billion by 2030.
The company said it continues to develop its infectious disease biosensor products, including for “pandemic threats” such as influenza A and coronavirus (COVID-19).” The influenza A program is supported by German grant funding through the calendar year.
In collaboration with third-party European medical product marketing and distribution firms, XPhyto is working to focus and “finalize its sales plan and to prioritize its biosensor development pipeline” as it targets commercialization of additional biosensor products for the European markets.
Delivery of XPhyto's biosensor products is accomplished using the company's oral thin film drug delivery platform. The firm said its ODF platform is “highly versatile, capable of delivering a wide-range of active pharmaceutical ingredients” in addition to the company's innovative biosensor molecules.
Oral thin film drug delivery is a large and growing international industry, which provides an alternative to conventional solid and liquid oral dosage forms. Transparency Market Research estimates that the global market for thin film drug manufacturing will be worth US$15.98 billion by 2024.
XPhyto's biosensor and drug delivery business is spearheaded by Professor Thomas Beckert, managing director of Vektor Pharma.
XPhyto is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. It has research and development operations in North America and Europe, with an operational focus in Germany.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive